WuXi AppTec Acquires Biology Focused R&D Service Leader HD Biosciences

Industry Reports

WuXi AppTec, a leading global pharmaceutical, biotechnology and medical device open-access capability and technology platform announced that it has acquired HD Biosciences (HDB), a leading biology focused preclinical drug discovery contract research organization (CRO).

After completion of acquisition, HD Biosciences will become a wholly-owned subsidiary of WuXi, and will continue to focus on growing its core competences and providing greater services. The acquisition will further strengthen WuXi’s R&D capability from target validation to lead discovery and optimization, improving and expanding WuXi’s open-access enabling service platform.

Founded in 2002, HD Biosciences is headquartered in Shanghai with operating facilities in Beijing and San Diego, USA. As a leading biology and preclinical service provider, its plate-based pharmacology & screening capability and AGMTM based target validation are industry leading platforms with great reputation. The company also provides hit identification, lead discovery, in vivo pharmacology and other related services.

HD Biosciences has long established close and strategic partnerships with major multinational pharmaceutical companies, biotechs and research institutions worldwide. Over the years, HD Biosciences has been providing award winning services to its worldwide clients, and has won a leading position among the biology CROs in China.

“We are excited about this acquisition and the great opportunities it brings along. HB Biosciences has a long-standing mission to grow into a major global player with distinctive core competences that could create special value for our clients. Merging with WuXi AppTec, a clear industry leader in drug R&D enabling services with enormous global exposure, resources and vision, will greatly speed up the process. We are confident that the integration will elevated our services to a new height and will enable us to better meet our growing customer needs,” said Dr. Xuehai Tan, Chairman and CEO of HD Biosciences.

“We are very pleased to welcome HD Biosciences to WuXi,” said Dr. Ge Li, Chairman and Chief Executive Officer of WuXi AppTec. “During the past 14 years, HD Biosciences has developed into a global company with wide recognition, and this business combination is an important step in strengthening WuXi’s biology and preclinical service capability. At WuXi, our commitment is to build the most comprehensive capability and technology platform in industry to enable anyone, and any company to discover and develop better medicines and healthcare products for patients, and to realize our vision that every drug can be made and every disease can be treated.”

About WuXi AppTec
WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities in small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics, WuXi platform is enabling nearly 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated."  Please visit http://www.wuxiapptec.com

Media Contacts:
Sunnie Sun, WuXi AppTec
This email address is being protected from spambots. You need JavaScript enabled to view it.


Market Movers

Rogers Corporation Common Stock

NYQ : ROG - 22 Mar, 4:02pm
+0.66 (+0.80%) After Hours:
Open 81.57 Mktcap 1.50B
High 83.13 52wk Hight 90.45
Low 81.47 52wk Low 51.98
Vol 73875 Avg Vol 103669
Eps 4.44 P/e 31.29
Currency: USD

Banco Santander, S.A. Sponsored

NYQ : SAN - 22 Mar, 4:02pm
+0.11 (+1.83%) After Hours:
Open 6.07 Mktcap 89.09B
High 6.16 52wk Hight 6.20
Low 6.04 52wk Low 3.60
Vol 9.26M Avg Vol 4.90M
Eps 0.49 P/e 14.08
Currency: USD

Merck & Company, Inc. Common St

NYQ : MRK - 22 Mar, 4:00pm
-0.41 (-0.64%) After Hours:
Open 63.98 Mktcap 174.34B
High 64.11 52wk Hight 66.80
Low 63.25 52wk Low 52.44
Vol 9.54M Avg Vol 10.66M
Eps 3.81 P/e 45.04
Currency: USD

Johnson & Johnson Common Stock

NYQ : JNJ - 22 Mar, 4:00pm
-0.99 (-0.78%) After Hours:
Open 127.17 Mktcap 342.59B
High 127.65 52wk Hight 129.00
Low 126.21 52wk Low 107.05
Vol 10.26M Avg Vol 6.92M
Eps 7.04 P/e 21.29
Currency: USD

Pfizer, Inc. Common Stock

NYQ : PFE - 22 Mar, 4:01pm
+0.22 (+0.64%) After Hours:
Open 34.30 Mktcap 205.16B
High 34.54 52wk Hight 37.39
Low 33.99 52wk Low 29.17
Vol 26.11M Avg Vol 24.69M
Eps 2.55 P/e 29.39
Currency: USD

Direxion Daily 10-Yr Treasury B

PCX : TYO - 22 Mar, 4:10pm
-0.1149 (-0.7665%) After Hours:
Open 14.8000 Mktcap
High 14.9000 52wk Hight 16.2930
Low 14.8000 52wk Low 12.6010
Vol 8936 Avg Vol 13947
Eps P/e
Currency: USD
Sign up via our free email subscription service to receive notifications when new information is available.